Clinical data | |
---|---|
Trade names | Eglonyl, Dolmatil, Sulpor |
AHFS/Drugs.com | International Drug Names |
Routes of administration |
Oral (tablets, capsules, oral solution), IM |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 25–40% |
Protein binding | <40% |
Metabolism | Not metabolised |
Biological half-life | 6-8 hours |
Excretion | Renal (70–90%),Fecal (~95% as the unchanged drug) |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.036.124 |
Chemical and physical data | |
Formula | C15H23N3O4S |
Molar mass | 341.427 g/mol |
3D model (Jmol) | |
|
|
|
|
Sulpiride (brand names Dogmatil ( DE, HK, SG, PH), Dolmatil (IE, UK), Eglonyl (RU, ZA), Espiride (ZA), Modal (IL), Prometar (UY), Sulpor (UK) and others) is an atypical antipsychotic drug (although some texts have referred to it as a typical antipsychotic) of the benzamide class used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression. Sulpiride is commonly used in Europe, Russia and Japan. Levosulpiride is its purified levo-isomer and is sold in India for similar purpose. So far it has not been approved in the United States, Canada and Australia. The drug is chemically and clinically similar to amisulpride.